A major milestone in obesity medicine research arrived quietly in early April 2026: the ClinicalTrials.gov listing for "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" (NCT05929066) officially changed its status from actively enrolling to completed, with a primary completion date of April 6, 2026. This is the TRIUMPH-4 trial — and its completion marks one of the most significant moments in the history of pharmacological obesity treatment.
Retatrutide, developed by Eli Lilly and Company under the compound name LY3437943, is a triple hormone receptor agonist — meaning it simultaneously activates receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Sometimes called a triple agonist or colloquially referred to as "triple G" in patient communities, this mechanism sets retatrutide apart from every other anti-obesity medication currently on the market. GLP-1 agonists like semaglutide act on a single receptor. Tirzepatide acts on two. Retatrutide acts on all three — and the clinical data suggest that distinction matters enormously.
TRIUMPH-4 enrolled adults with obesity (BMI ≥30 kg/m²) or overweight with at least one weight-related comorbidity. Participants received once-weekly subcutaneous injections of retatrutide at doses of 9mg or 12mg, or placebo, over a 68-week treatment period. The trial used a careful step-up titration schedule: 2mg for weeks 1–4, advancing to 4mg, then 6mg, then 9mg, before reaching the 12mg maintenance dose at week 17. This gradual escalation was designed to minimize the gastrointestinal side effects — nausea, vomiting, diarrhea — that are characteristic of this drug class.
The ClinicalTrials.gov entry for NCT05929066 now reflects completed status, confirming that data collection for the primary endpoint has concluded. A peer-reviewed publication of the full Phase 3 results is pending as of April 2026.
According to an Eli Lilly press release issued December 11, 2025, TRIUMPH-4 produced a mean weight loss of 28.7% at the 12mg dose over 68 weeks — the highest mean weight loss ever recorded in a Phase 3 randomized controlled trial for obesity. To put that number in clinical context, a person weighing 250 pounds at baseline would, on average, lose approximately 72 pounds.
That figure does not exist in isolation. The Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.; NCT04881760) already suggested this trajectory was possible. At 48 weeks in Phase 2, the 12mg arm achieved mean weight loss of 24.2%, with 64% of participants losing ≥20% of body weight and 48% losing ≥25%. At the 8mg dose, 70% of participants lost ≥20% of body weight — a figure that exceeded the entire efficacy ceiling of most prior anti-obesity medications.
The table below places the TRIUMPH-4 result alongside benchmarks from the landmark Phase 3 trials of the two currently approved injectable obesity medications:
| Drug | Trial | Duration | Top Dose | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | STEP-1 | 68 weeks | 2.4mg weekly | ~14.9% |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | 15mg weekly | ~20.9% |
| Retatrutide 12mg | TRIUMPH-4 | 68 weeks | 12mg weekly | ~28.7% |
Beyond weight loss, Phase 2 data demonstrated meaningful improvements in cardiometabolic markers. At 24 weeks, the 12mg dose reduced fasting triglycerides by 34.0% and total cholesterol by 17.3%. LDL cholesterol fell by 15.6–16.9% in the 8mg arms. Quality of life scores, measured by the SF-36v2, improved across all active dose groups at week 48.
On the safety side, the most common adverse events were gastrointestinal — nausea, diarrhea, and vomiting — consistent with the GLP-1 class and largely dose-dependent, peaking during the titration phase. A notable finding at higher doses was dysesthesia (abnormal skin sensations): reported in 20.9% of the 12mg group versus 0.7% of placebo participants in TRIUMPH-4, and 12.9% versus 1.4% placebo in Phase 2. This side effect warrants careful monitoring and informed patient counseling. Discontinuation rates in TRIUMPH-4 were 18.2% at 12mg and 12.2% at 9mg, compared to 4.0% for placebo — with some discontinuations attributed to perceived excessive weight loss, an outcome rarely encountered in obesity pharmacotherapy.
Importantly, these Phase 2 results excluded individuals with type 2 diabetes. Separate retatrutide trials in diabetic populations have also been conducted; however, data from those studies are not incorporated here.
Completing a Phase 3 trial is a critical — but not final — step on the path to FDA approval. Lilly must compile the complete TRIUMPH program data package and submit a New Drug Application (NDA) to the FDA. As of April 2026, no NDA has been filed, and no FDA approval timeline has been publicly confirmed.
Following NDA submission, the FDA typically completes a standard review within 10–12 months, though Priority Review designation — which the agency may grant given the public health burden of obesity — can shorten that window to approximately six months. The peer-reviewed Phase 3 publication is also pending, which will allow the scientific and medical community to scrutinize the full dataset, including subgroup analyses, safety follow-up, and any secondary endpoint results not yet disclosed.
In short: the science has cleared one of its highest hurdles. The regulatory process is next, and it takes time. Patients and clinicians tracking retatrutide should expect continued development activity through 2026 and into 2027.
No confirmed launch date exists. What is known is that the drug commonly referred to as reta in patient communities has now completed its largest Phase 3 trial with the most impressive mean weight loss figure ever recorded in this therapeutic category. The conversation in obesity medicine has shifted — not to whether retatrutide works, but to how quickly it can reach the patients who need it.
For the millions of people living with obesity who have struggled with food noise, weight regain, or inadequate response to existing therapies, this moment represents genuine, evidence-based hope. The glucagon receptor component — the element that distinguishes retatrutide from tirzepatide — appears to drive additional energy expenditure beyond what GLP-1 and GIP activation alone can achieve, potentially explaining the magnitude of these results.
Monitoring the TRIUMPH program, the NDA filing, and FDA communications will be essential as 2026 progresses. glp3md.com will continue publishing clinical updates as peer-reviewed data and regulatory developments become available.
If retatrutide is on your radar, the glp3md.com waitlist exists to keep you informed as the regulatory and clinical landscape evolves. Joining the waitlist means receiving timely, evidence-based updates about retatrutide's development — including NDA filing news, FDA decisions, and clinical availability. Please note: joining the waitlist is for informational purposes only. No promises are made regarding treatment, medication access, or prescriptions. Retatrutide is not FDA-approved and is not currently available as a commercial therapy. Visit https://www.glp3md.com to add your name and stay ahead of one of the most significant advances in obesity medicine in a generation.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.